Given Anika Therapeutics' history of beating EPS estimates and the subsequent positive impact on its share price, the Q4 earnings beat is likely to result in a short-term positive movement in ANIK's stock price. The significant outperformance in earnings and the year-over-year revenue growth are key indicators of the company's strong financial health and operational efficiency, which are critical factors investors consider.